An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumours (METADUR)
This is a phase 2 study of investigational drug, durvalumab given in combination with
azacitidine (CC-486). The main purpose of this phase 2 study is to assess the antitumour
activity of azacitidine in combination with durvalumab patients with microsatellite stable
colorectal carcinoma (MSS-CRC), platinum resistant epithelial ovarian cancer type II
(PR-OC), and estrogen receptor positive and HER2 negative breast cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society